Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...

For the last couple of years, the pharmaceutical sector has become infatuated with glucagon-like peptide 1 (GLP-1) agonists used to treat diabetes and help with chronic weight management.

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly(NYSE ... a much more accelerated rate than Lilly's business as a whole. One of the primary drivers for Verzenio's ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click here to read why LLY is a Buy.

Scientists recently studied how different factors affect antisense oligonucleotides (ASOs) under hydrophilic interaction ...

I'm Chris Schott at JPMorgan and it's my pleasure to be hosting this fireside chat today with Dave Ricks, Chairman and CEO of Eli ... about Lilly's capacity buildup. I think it's a key one ...